AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceutical.

CSPC is one of the largest and oldest pharmaceutical companies in China. Anchored by its nervous system business segment due to its flagship drug NBP, CSPC has a portfolio of innovative and ...

CSPC Pharma was already on track for a tough earnings season after its nine-month profits fell 15.9% Another blow was the sudden departure of the firm's head of innovative drug research, Liu ...

CSPC PHARMA (01093.HK) announced that JMT108, a new Class I bi-functional fusion protein drug developed by the group, has been approved by the National Medical Products Administration to conduct ...